drugset / Trial / NCT05555862
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Phase 2
Active not recruiting
17 enrolled
Frantz Viral Therapeutics, LLC
Amarex CRO · collabAnal Dysplasia Clinic MidWest · collabLaser Surgery Care · collabUniversity of California, San Francisco · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Timeline
- Start
- 2023-02-10
- Primary completion
- 2026-12-28
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | — | Other |